Coming Soon: Innovative Technologies in the Field of Bio-Convergence

Novel Solutions Coming Soon: Innovative Technologies in the Field of Bio-Convergence

2022-05-26 Source: Press release Ahlam Rais

Related Vendors

Ben-Gurion University of the Negev

DÜPERTHAL Sicherheitstechnik GmbH & Co. KG

Xylem Analytics Germany Sales GmbH & Co. KG

Bimos - eine Marke der Interstuhl Büromöbel GmbH & Co. KG

Ben-Gurion University of the Negev (BGU) has partnered with the Soroka Medical Center to develop novel technologies in the bio-convergence space, a field that combines biology with computational technologies and engineering.

Ben-Gurion University of the Negev (BGU) and Soroka Medical Center have announced a strategic collaboration for the development of novel technologies in the field of Bio-Convergence.(Source: Pixabay) — Ben-Gurion University of the Negev (BGU) and Soroka Medical Center have announced a strategic collaboration for the development of novel technologies in the field of Bio-Convergence.
(Source: Pixabay)

Be'er Sheva/Israel – Ben-Gurion University of the Negev (BGU) and Soroka Medical Center have announced a strategic collaboration for the development of novel technologies in the field of Bio-Convergence (a field that combines biology with computational technologies and engineering). The selected projects under the collaboration will be funded by the British philanthropic fund Rosetrees Trust.

BGN Technologies, the technology transfer company of BGU, will accompany the projects from their inception in various commercialization aspects including intellectual property protection and business development activities.

One of the first projects to be chosen is led by Prof. Lital Alfonta from the Department of Life Sciences at BGU and Dr. Orna Staretz-Chacham, the Metabolic Clinic, Pediatric Division, Soroka University Medical Center. The project aims at developing a non-invasive home test for immediate monitoring of the orphan condition Maple Syrup Urine Disease (MSUD).

MSUD is a serious genetic condition caused by a deficiency of the enzyme Keto-acid-dehydrogenase. Blood tests show high levels of three amino acids (leucine, isoleucine, and valine), that can lead to life-threatening cerebral oedema and dysmyelination in affected individuals. The disease is more common in Ashkenazi Jews, and in the Bedouin population in the South region of Israel. Children with MSUD must remain on a special diet that restricts the consumption of those three amino acids.

Currently, the amino acid levels of children with MSUD are monitored weekly at the hospital, and the results arrive only after several days. Prof. Alfonta is developing a technology based on bioelectrochemistry, which combines optimization of protein function with synthetic biology tools in order to create accurate and specific sensors for immediate monitoring of the relevant amino acids.

This will enable real-time diet recommendations and forgo the need for a weekly hospital visit. In addition, neonates are routinely scanned for amino acid levels, and the novel technology can supply immediate results. Immediate monitoring of amino acids is especially crucial in the developmental phase of people (i.e. children and neonates)

A joint team from both institutes mapped the daily medical needs of Soroka on the one hand, and the current challenges of the pharma and Healthtech industries on the other. In response to these needs and challenges, the collaboration tailors applied, Bio-Convergence projects with large potential for future commercialization.

Josh Peleg, CEO of BGN Technologies, said, "In addition to the synergy between disciplines and strengths of the two institutions leading to innovation in the field of Bio-Convergence, this unique collaboration also emphasizes applicable technologies. The first step is mapping the needs of current medicine, both in hospitals and the biopharma industry, after which we turn to the researchers in order to find a solution to the problem. The involvement of BGN Technologies from the initial stages of project selection will enable to maximize the commercial feasibility of the funded inventions. In addition, we will accompany each project in terms of business development and intellectual property protection. Our role is to bridge the existing gap between academia and industry."

Bio-convergence is a multi-disciplinary combination of biology, engineering, electronics, artificial intelligence, computational biology, physics, nanotechnology, materials science, and genetic engineering. The synergy between biology and engineering is considered today as the forefront of medical science and development.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:48389815)